1. Scrip

Chindia Generics: A Dream or Reality?

 
• By Brian Yang and Anju Ghangurde

Meeting and greeting is necessary, as is the right form of partnership and getting everyone on board. But as Indian drug makers learn the ropes of entering the complex Chinese market, the seemingly natural fit may still have a long way to go.

Money Wave
Chindia Generics a dream or reality? • Source: Shutterstock

It seems logical for the two largest pharma suppliers in the world, one of active ingredients and another of generic drugs, to trade more, but forward movement between the Indian and Chinese industries may not be straightforward.

Indian firms are hoping to finally enter China’s generics market after years of testing the waters, while China is hoping...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

S&E In Brief: Launch Updates And Political Headwinds

 
• By Sushmita Panda

Madrigal and Syndax update investors on their key launches, while Merck KGaA weighs in on the possibility of direct-to-consumer sales in the US.

Another Day Another Win For Novartis’s Ianalumab – This Time In ITP

 
• By Aakash Babu

The Swiss drugmaker’s BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate has chalked up another win in late-stage development, further strengthening its pipeline-in-a-product bid.

Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study

 
• By Alaric DeArment

The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.